CZChi Zhang

Chi Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chi Zhang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Dousheng Bai

    Department of Hepatobiliary Surgery, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, China

    11 shared publications
  • Jun Cao

    Department of Hepatobiliary Surgery, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, China

    8 shared publications
  • Rui Peng

    Department of Hepatobiliary Surgery, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, China

    7 shared publications
  • Jie Zhou

    Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou, China

    6 shared publications
  • Qian Wang

    Department of Hepatobiliary Surgery, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, China

    6 shared publications
  • Bingbing Su

    Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou, China

    5 shared publications

Latest Publications

  • Enhanced prediction of 5-year postoperative recurrence in hepatocellular carcinoma by incorporating LASSO regression and random forest models

    by Bing-Bing Su, Chao-Jie Zhu, Jun Cao, Rui Peng, Dao-Yuan Tu, Guo-Qing Jiang, Sheng-Jie Jin, Qian Wang, Chi Zhang, Dou-Sheng Bai

    Background Tumor recurrence post-operation of hepatocellular carcinoma (HCC) impacts patient prognosis. Identifying and predicting 5-year HCC recurrence following surgery remains a substantial challenge. Methods We included 338 patients diagnosed with HCC who underwent surgery from January 2013 to December 2018. Traditional logistic regression, random forest (RF), and LASSO regression methods were used to develop a predictive model for 5-year recurrence. The findings were presented visually using nomogram. The accuracy and sensitivity of the predictive model were evaluated by receiver operating curves (ROC) and decision curve analysis (DCA). Results Of the 338 patients, 172 (50.9%) experienced 5 years recurrence, with a gender distribution of 79.7% males. Univariate and multivariate logistic regression analysis identified that three independent predictors of 5-year HCC recurrence (all P < 0.001). The area under the curve (AUC) value of the model (Model-1) constructed was 0.678. Then we combined LASSO regression and RF construct a predictive model including six factors: age, transarterial chemoembolization (TACE), microvascular invasion (MVI), alcohol, size, and number. The AUC of the model (Model-2) constructed was 0.733. DeLong’s test results showed that Model-2 had significantly better prediction ability compared with Model-1 (P = 0.004). DCA also demonstrated that Model-2 had better predictive accuracy (P < 0.05). Then we constructed a nomogram, and Kaplan–Meier analysis showed that patients in the low-risk group had significantly better prognosis than the high (P < 0.001). Conclusion The predictive accuracy of our model, incorporating factors, such as age, alcohol, size, number, MVI, and TACE, significantly enhances clinical practice management by accurately forecasting 5 years HCC recurrence.


  • Open Access

    Degradation of PARP1 by MARCHF3 in tumor cells triggers cCAS-STING activation in dendritic cells to regulate antitumor immunity in hepatocellular carcinoma

    by Jun Cao, Bingbing Su, Chi Zhang, Rui Peng, Daoyuan Tu, Qiangwei Deng, Guoqing Jiang, Shengjie Jin, Qian Wang, Dou-Sheng Bai

    Background: Resistance to immune checkpoint inhibitors (ICIs) significantly limits the efficacy of immunotherapy in patients with hepatocellular carcinoma (HCC). However, the mechanisms underlying immunotherapy resistance remain poorly understood. Our aim was to clarify the role of membrane-associated ring-CH-type finger 3 (MARCHF3) in HCC within the framework of anti-programmed cell death protein-1 (PD-1) therapy. Methods: MARCHF3 was identified in the transcriptomic profiles of HCC tumors exhibiting different responses to ICIs. In humans, the correlation between MARCHF3 expression and the tumor microenvironment (TME) was assessed via multiplex immunohistochemistry. In addition, MARCHF3 expression in tumor cells and immune cell infiltration were assessed by flow cytometry. Results: MARCHF3 was significantly upregulated in tumors from patients who responded to ICIs. Increased MARCHF3 expression in HCC cells promoted dendritic cell (DC) maturation and stimulated CD8+ T-cell activation, thereby augmenting tumor control. Mechanistically, we identified MARCHF3 as a pivotal regulator of the DNA damage response. It directly interacted with Poly(ADP-Ribose) Polymerase 1 (PARP1) via K48-linked ubiquitination, leading to PARP1 degradation. This process promoted the release of double-strand DNA and activated cCAS-STING in DCs, thereby initiating DC-mediated antigen cross-presentation and CD8+ T-cell activation. Additionally, ATF4 transcriptionally regulated MARCHF3 expression. Notably, the PARP1 inhibitor olaparib augmented the efficacy of anti-PD-1 immunotherapy in both subcutaneous and orthotopic HCC mouse models. Conclusions: MARCHF3 has emerged as a pivotal regulator of the immune landscape in the HCC TME and is a potent predictive biomarker for HCC. Combining interventions targeting the DNA damage response with ICIs is a promising treatment strategy for HCC.


  • Strategic advancement of E3 ubiquitin ligase in the management of hepatocellular carcinoma

    by Yangyang Miao, Shunyi Wang, Jiahao Zhang, Huanxiang Liu, Chi Zhang, Shengjie Jin, Dousheng Bai

    Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its high incidence, poor prognosis, and limited treatment options. As a pivotal regulator of protein stability, E3 ubiquitin ligase plays a crucial role in tumorigenesis and development. This review provides an overview of the latest research on the involvement of E3 ubiquitin ligase in hepatocellular carcinoma and elucidates its significance in hepatocellular carcinoma cell proliferation, invasion, and evasion from immune surveillance. Special attention is given to the functions of RING, HECT, and RBR E3 ubiquitin ligases and their association with hepatocellular carcinoma progression. By dissecting the molecular mechanisms and regulatory networks governed by E3 ubiquitin ligase, several potential therapeutic strategies are proposed: including the development of specific inhibitors targeting E3 ligases; augmentation of their tumor suppressor activity through drug or gene therapy; utilization of E3 ubiquitin ligase to modulate immune checkpoint proteins for improved efficacy of immunotherapy; combination strategies integrating traditional therapies with E3 ubiquitin ligase inhibitors; as well as biomarker development based on E3 ubiquitin ligase activity. Furthermore, this review discusses the prospect of overcoming drug resistance in hepatocellular carcinoma treatment through these novel approaches. Overall, this review establishes a theoretical foundation and offers fresh insights into harnessing the potential of E3 ubiquitin ligase for treating hepatocellular carcinoma while highlighting future research directions that pave the way for clinical translation studies and new drug discoveries.


  • Open Access

    Establishment of a circRNA-regulated E3 ubiquitin ligase signature and nomogram to predict immunotherapeutic efficacy and prognosis in hepatocellular carcinoma

    by Gefeng Wu, Jiahao Zhang, Rui Peng, Jun Cao, Daoyuan Tu, Jie Zhou, Bingbing Su, Shengjie Jin, Guoqing Jiang, Chi Zhang, et al.

    Background: Hepatocellular carcinoma (HCC) is a common type of malignant tumor where the prognosis is dismal. Circular RNA (CircRNA) is a novel RNA that regulates downstream gene transcription and translation to influence the progression of HCC. However, the regulatory relationship that exists between E3 ligases, which is a class of post-translational modifying proteins, and circRNA remains unclear. Methods: Based on the E3 ubiquitin ligase in the competitive endogenous RNA (ceRNA) network, a circRNA-regulated E3 ubiquitin ligase signature (CRE3UL) was developed. A CRE3UL signature was created using the least absolute shrinkage and selection operator (Lasso) and Cox regression analysis and merged it with clinicopathologic characteristics to generate a nomogram for prognosis prediction. The pRRophetic algorithm was utilized and immunological checkpoints were analyzed to compare the responses of patients in the high-risk group (HRG) and low-risk group (LRG) to targeted therapy and immunotherapy. Finally, experimental research will further elucidate the relationship between E3 ubiquitin ligase signature and HCC. Results: HRG patients were found to have a worse prognosis than LRG patients. Furthermore, significant variations in prognosis were observed among different subgroups based on various clinical characteristics. The CRE3UL signature was identified as being an independent prognostic indicator. The nomogram that combined clinical characteristics and the CRE3UL signature was found to accurately predict the prognosis of HCC patients and demonstrated greater clinical utility than the current TNM staging approach. According to anticancer medication sensitivity predictions, the tumors of HRG patients were more responsive to gefitinib and nilotinib. From immune-checkpoint markers analysis, immunotherapy was identified as being more probable to assist those in the HRG. Conclusions: We found a significant correlation between the CRE3UL signature and the tumor microenvironment, enabling precise prognosis prediction for HCC patients. Additionally, a nomogram was developed that performs well in predicting the overall survival (OS) of HCC patients. This provides valuable guidance for clinicians in devising specific personalized treatment strategies. Graphical

  • TRIM5 as a promising diagnostic biomarker of hepatocellular carcinoma: integrated analysis and experimental validation

    by Huanxiang Liu, Yuhong Tang, Jiahao Zhang, Gefeng Wu, Qing Peng, Chen Chen, Jun Cao, Rui Peng, Bingbing Su, Daoyuan Tu, et al.

    The TRIM family is associated with the membrane, and its involvement in the progression, growth, and development of various cancer types has been researched extensively. However, the role played by the TRIM5 gene within this family has yet to be explored to a great extent in terms of hepatocellular carcinoma (HCC). The data of patients relating to mRNA expression and the survival rate of individuals diagnosed with HCC were extracted from The Cancer Genome Atlas (TCGA) database. UALCAN was employed to examine the potential link between TRIM5 expression and clinicopathological characteristics. In addition, enrichment analysis of differentially expressed genes (DEGs) was conducted as a means of deciphering the function and mechanism of TRIM5 in HCC. The data in the TCGA and TIMER2.0 databases was utilized to explore the correlation between TRIM5 and immune infiltration in HCC. WGCNA was performed as a means of assessing TRIM5-related co-expressed genes. The "OncoPredict" R package was also used for investigating the association between TRIM5 and drug sensitivity. Finally, qRT-PCR, Western blotting (WB) and immunohistochemistry (IHC) were employed for exploring the differential expression of TRIM5 and its clinical relevance in HCC. According to the results that were obtained from the vitro experiments, mRNA and protein levels of TRIM5 demonstrated a significant upregulation in HCC tissues. It is notable that TRIM5 expression levels were found to have a strong association with the infiltration of diverse immune cells and displayed a positive correlation with several immune checkpoint inhibitors. The TRIM5 expression also displayed promising clinical prognostic value for HCC patients.


  • Open Access

    A Novel Scoring Model of Deubiquitination Patterns Predicts Prognosis and Immunotherapeutic Response in Hepatocellular Carcinoma

    by Jiahao Zhang, Gefeng Wu, Rui Peng, Jun Cao, Daoyuan Tu, Jie Zhou, Bingbing Su, Shengjie Jin, Guoqing Jiang, Chi Zhang, et al.


  • Open Access

    RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma

    by Jie Zhou, Daoyuan Tu, Rui Peng, Yuhong Tang, Qiangwei Deng, Bingbing Su, Shunyi Wang, Hao Tang, Shengjie Jin, Guoqing Jiang, et al.

    Background: The role of the membrane-associated RING-CH (MARCH) family in carcinogenesis has been widely studied, but the member of this family, RNF173, has not yet been thoroughly explored in the context of hepatocellular carcinoma (HCC). Methods: With the use of an HCC tissue microarray and IHC staining, we aim to determine the differential expression of RNF173 in HCC patients and its clinical significance. The biological role of RNF173 is investigated through in vitro and in vivo experiments. RNA sequencing, mass spectrometry, and immunoprecipitation are performed to uncover the underlying mechanism of RNF173's impact on the development of HCC. Results: The mRNA and protein levels of RNF173 were significantly lower in HCC tissues than in normal tissues. HCC patients with low RNF173 expression had shorter overall survival and recurrence-free survival, and RNF173 was significantly correlated with tumor number, tumor capsule, tumor differentiation, and BCLC stage. In addition, in vitro and in vivo experiments showed that RNF173 downregulation exacerbated tumor progression, including migration, invasion, and proliferation. GRB2 is a key molecule in the RAF/MEK/ERK pathway. RNF173 inhibits the RAF/MEK/ERK signaling by ubiquitinating and degrading GRB2, thereby suppressing HCC cell proliferation, invasion and migration. Combining clinical samples, we found that HCC patients with high RNF173 and low GRB2 expression had the best prognosis. Conclusion: RNF173 inhibits the invasion and metastasis of HCC by ubiquitinating and degrading GRB2, thereby suppressing the RAF/MEK/ERK signaling pathway. RNF173 is an independent risk factor for the survival and recurrence of HCC patients. RNF173 may serve as a novel prognostic molecule and potential therapeutic target for HCC. Graphical Graphical abstract Model of RNF173 on RAF/MEK/ERK signaling. RNF173 knockdown resulted in impaired ubiquitination and degradation of GRB2, leading to the activation of the RAF/MEK/ERK signaling pathway and promotion of invasion and metastasis in HCC cells.


  • Open Access

    Identification of the mitophagy-related diagnostic biomarkers in hepatocellular carcinoma based on machine learning algorithm and construction of prognostic model

    by Dao-Yuan Tu, Jun Cao, Jie Zhou, Bing-Bing Su, Shun-Yi Wang, Guo-Qing Jiang, Sheng-Jie Jin, Chi Zhang, Rui Peng, Dou-Sheng Bai

    Background and aims: As a result of increasing numbers of studies most recently, mitophagy plays a vital function in the genesis of cancer. However, research on the predictive potential and clinical importance of mitophagy-related genes (MRGs) in hepatocellular carcinoma (HCC) is currently lacking. This study aimed to uncover and analyze the mitophagy-related diagnostic biomarkers in HCC using machine learning (ML), as well as to investigate its biological role, immune infiltration, and clinical significance.Methods: In our research, by using Least absolute shrinkage and selection operator (LASSO) regression and support vector machine- (SVM-) recursive feature elimination (RFE) algorithm, six mitophagy genes (ATG12, CSNK2B, MTERF3, TOMM20, TOMM22, and TOMM40) were identified from twenty-nine mitophagy genes, next, the algorithm of non-negative matrix factorization (NMF) was used to separate the HCC patients into cluster A and B based on the six mitophagy genes. And there was evidence from multi-analysis that cluster A and B were associated with tumor immune microenvironment (TIME), clinicopathological features, and prognosis. After then, based on the DEGs (differentially expressed genes) between cluster A and cluster B, the prognostic model (riskScore) of mitophagy was constructed, including ten mitophagy-related genes (G6PD, KIF20A, SLC1A5, TPX2, ANXA10, TRNP1, ADH4, CYP2C9, CFHR3, and SPP1). Results: This study uncovered and analyzed the mitophagy-related diagnostic biomarkers in HCC using machine learning (ML), as well as to investigate its biological role, immune infiltration, and clinical significance. Based on the mitophagy-related diagnostic biomarkers, we constructed a prognostic model(riskScore). Furthermore, we discovered that the riskScore was associated with somatic mutation, TIME, chemotherapy efficacy, TACE and immunotherapy effectiveness in HCC patients.Conclusion: Mitophagy may play an important role in the development of HCC, and further research on this issue is necessary. Furthermore, the riskScore performed well as a standalone prognostic marker in terms of accuracy and stability. It can provide some guidance for the diagnosis and treatment of HCC patients.


  • Open Access

    Comprehensive analysis of the clinical significance, immune infiltration, and biological role of MARCH ligases in HCC

    by Jun Cao, Dao-Yuan Tu, Jie Zhou, Guo-Qing Jiang, Sheng-Jie Jin, Bing-Bing Su, Hao Tang, Yu-Hong Tang, Ao-Qing Wang, Qian Wang, et al.

    The membrane‐associated RING‐CH (MARCH) family, a member of the E3 ubiquitin ligases, has been confirmed by a growing number of studies to be associated with immune function and has been highlighted as a potential immunotherapy target. In our research, hepatocellular carcinoma (HCC) patients were divided into C1 and C2 MARCH ligase-related patterns by the non-negative matrix factorization (NMF) algorithm. Multiple analyses revealed that the MARCH ligase-related cluster was related to prognosis, clinicopathological characteristics, and the tumor immune microenvironment (TIME). Next, the signature (risk score) of the MARCH prognosis was constructed, including eight genes associated with the MARCH ligase (CYP2C9, G6PD, SLC1A5, SPP1, ANXA10, CDC20, PON1, and FTCD). The risk score showed accuracy and stability. We found that the correlations between risk score and TIME, tumor mutation burden (TMB), prognosis, and clinicopathological characteristics were significant. Additionally, the risk score also had important guiding significance for HCC treatment, including chemotherapy, immunotherapy, and transarterial chemoembolization (TACE).


  • Open Access

    Bioinformatics analysis of immune infiltrates and tripartite motif (TRIM) family genes in hepatocellular carcinoma

    by Jun Cao, Bingbing Su, Rui Peng, Hao Tang, Daoyuan Tu, Yuhong Tang, Jie Zhou, Guoqing Jiang, Shengjie Jin, Qian Wang, et al.

    Original Article Bioinformatics analysis of immune infiltrates and tripartite motif (TRIM) family genes in hepatocellular carcinoma Jun Cao, Bingbing Su, Rui Peng, Hao Tang, Daoyuan Tu, Yuhong Tang, Jie Zhou, Guoqing Jiang, Shengjie Jin, Qian Wang, Aoqing Wang, Renjie Liu, Qiangwei Deng, Chi Zhang, Dousheng Bai